As a competitor encroached, Mylan took one state to court to push EpiPen sales, documents
From the article:
Three lawyers who reviewed the case at the request of STAT said they could not think of another instance when a pharmaceutical company sued to protect the status of its medication on a state formulary.
“This is another really good example of how Mylan has attempted to use the law to their advantage at every turn to expand their market share,” said Rachel Sachs, an associate professor at the Washington University in St. Louis School of Law who specializes in health law. [...]
Read the full article here.bioethics fda health care finance health care reform market pharmaceuticals public health rachel sachs regulation